|
For the
|
For the
|
|||||||||||||
| (in 000) | 2018 | 2017 | 2018 | 2017 | ||||||||||
| € | € | € | € | |||||||||||
| Net profit (loss) for the period | 2,316 | (1,413 | ) | 2,502 | (3,184 | ) | ||||||||
| Income taxes | 230 | 433 | 773 | 825 | ||||||||||
| Financial expenses | 1,039 | 1,058 | 3,556 | 3,294 | ||||||||||
| Financial income | (1,308 | ) | (465 | ) | (2,739 | ) | (2,132 | ) | ||||||
| Share in loss of joint venture | 47 | 165 | 291 | 596 | ||||||||||
| Depreciation and amortization | 4,519 | 2,918 | 12,534 | 8,142 | ||||||||||
| EBITDA | 6,843 | 2,696 | 16,917 | 7,541 | ||||||||||
| Non-cash stock-based compensation expense (1) | 191 | 297 | 557 | 997 | ||||||||||
| Acquisition-related expenses (2) | − | 266 | − | 266 | ||||||||||
| ADJUSTED EBITDA | 7,034 | 3,259 | 17,474 | 8,804 | ||||||||||
| (1) | Non-cash stock-based compensation expenses represent the cost of equity-settled and cash-settled share-based payments to employees. | |||||
| (2) | Acquisition-related expenses of business combinations represent expenses incurred in connection with the ACTech acquisition. | |||||
|
Segment P&L (Unaudited) |
||||||||||||||||||||
| (in 000) |
Materialise
Software |
Materialise
Medical |
Materialise
Manufact- uring |
Total
|
Unallocated(1) |
Consoli-
dated |
||||||||||||||
| € | € | € | € | € | € | |||||||||||||||
| For the nine months ended September 30, 2018 | ||||||||||||||||||||
| Revenues | 27,331 | 37,170 | 71,031 | 135,532 | 175 | 135,707 | ||||||||||||||
| Segment EBITDA | 8,567 | 6,659 | 8,802 | 24,028 | (7,111 | ) | 16,917 | |||||||||||||
|
Segment EBITDA % |
31.3 | % | 17.9 | % | 12.4 | % | 17.7 | % | 12.5 | % | ||||||||||
| For the nine months ended September 30, 2017 | ||||||||||||||||||||
| Revenues | 25,302 | 30,999 | 41,318 | 97,619 | 221 | 97,840 | ||||||||||||||
| Segment EBITDA | 9,307 | 2,242 | 3,062 | 14,611 | (7,070 | ) | 7,541 | |||||||||||||
|
Segment EBITDA % |
36.8 | % | 7.2 | % | 7.4 | % | 15.0 | % | 7.7 | % | ||||||||||
| (1) | Unallocated Revenues consist of occasional one-off sales by our core competencies not allocated to any of our segments. Unallocated Segment EBITDA consists of corporate research and development, corporate headquarter costs and net other operating income (expense). | |
| (in 000) |
Materialise
Software |
Materialise
Medical |
Materialise
Manufact- uring |
Total
|
Unallocated(1) |
Consoli-
dated |
||||||||||||||
| € | € | € | € | € | € | |||||||||||||||
| For the three months ended September 30, 2018 | ||||||||||||||||||||
| Revenues | 9,874 | 12,824 | 24,012 | 46,710 | 22 | 46,732 | ||||||||||||||
| Segment EBITDA | 3,384 | 2,475 | 3,405 | 9,264 | (2,420 | ) | 6,844 | |||||||||||||
|
Segment EBITDA % |
34.3 | % | 19.3 | % | 14.2 | % | 19.8 | % | 14.6 | % | ||||||||||
| For the three months ended September 30, 2017 | ||||||||||||||||||||
| Revenues | 8,422 | 10,421 | 13,456 | 32,299 | 8 | 32,307 | ||||||||||||||
| Segment EBITDA | 3,362 | 1,170 | 499 | 5,031 | (2,335 | ) | 2,696 | |||||||||||||
|
Segment EBITDA % |
39.9 | % | 11.2 | % | 3.7 | % | 15.6 | % | 8.3 | % | ||||||||||
| (1) | Unallocated Revenues consist of occasional one-off sales by our core competencies not allocated to any of our segments. Unallocated Segment EBITDA consists of corporate research and development, corporate headquarter costs and net other operating income (expense). | |
